Naloxone but not CCK-8 may attenuate binge-eating behavior in patients with the bulimia syndrome

Mitchell, James E.; Laine, Dawn; Morley, John E.; Levine, A. S.

doi:10.1016/0006-3223(86)90331-8

Cited by 86 publications

(25 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mitchell, Pyle, et al (1989), spurred by preliminary work indicating that intravenous (I.V.) opiate antagonists decrease the duration and quantity of food eaten during a binge meal (Mitchell, Laine, Morley, & Levine, 1986), attempted to use naltrexone (50 mg) in a cross-over study of 18 women with bulimia nervosa. There was not a significant advantage for either drug or placebo.…”

Section: Pharmacotherapy Studiesmentioning

confidence: 99%

A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa

Mitchell

Raymond

Specker

1993

Int. J. Eat. Disord.

Self Cite

View full text Add to dashboard Cite

The treatment literature on bulimia nervosa includes several double‐blind placebo controlled studies, the majority of which examine the use of antidepressants in bulimia nervosa. The psychotherapy literature has focused heavily on the use of cognitive behavioral therapy (CBT) in the treatment of this eating disorder. Some studies have compared CBT to other types of therapy or waiting list controls. The following review will examine the methodology and outcome of the pharmacotherapy and psychotherapy treatment studies of bulimia nervosa. The authors conclude that while the studies indicate treatment is somewhat effective, there remains uncertainty regarding the long‐term effectiveness of most of the reported treatments. © 1993 by John Wiley & Sons, Inc.

show abstract

Section: Pharmacotherapy Studiesmentioning

confidence: 99%

A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa

Mitchell

Raymond

Specker

1993

Int. J. Eat. Disord.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mitchell et al [29] found that bulimic patients were resistant to the anorectiv effects of CCK during a binge. Geraciotti and Liddle [30] reported that patients with bulimia nervosa do not have normal satiety in response to a meal and that in these subjects the CCK response to a meal is significantly impaired.…”

Section: The Peripheral Satiety Systemmentioning

confidence: 99%

“…19 for a review], Flowever, attempts to treat obesity with long-acting opioid antagonists have failed [40]. Unlike CCK, naloyone does decrease the size of the binge in bulimic patients [29]. However, despite an open study which suggested that naltrexone may be useful in therapy of bulimia [41], we had a relatively poor response to long-term naltrexone used at a lower dose in a double-blind study [42], Whether the develop ment of selective kappa antagonists will result in more useful anorectic agents remains to be determined.…”

Section: Central Appetite Stimulantsmentioning

confidence: 99%

An Approach to the Development of Drugs for Appetite Disorders

Money

1989

Neuropsychobiology

View full text Add to dashboard Cite

This review covers some modern concepts in the development of drugs to treat appetite disorders. Specific attention is paid to the peripheral satiety system and the role of gastrointestinal peptides such as cholecystokinin in the pathogenesis of satiety. Alterations in neuropeptide Y and/or peptide YY are suggested to play a role in the pathophysiology of bulimia. Corticotropin-releasing factor is a putative candidate peptide involved in anorexia nervosa. The serotonin reuptake inhibitors fenfluramine and fluoxetene decrease weight in obese subjects. Endogenous opioids modulate the choice of palatable foods. Anorexia in the old appears to be related to a decrease in opioid feeding drive and an excess of the satiety action of cholecystokinin. Other agents involved in weight regulation include those which alter gastric emptying, increase thermogenesis, or modulate fat cell metabolism. It should be stressed that many neurotransmitters that modulate appetite also alter other behaviors, increasing their propensity to produce side effects.

show abstract

“…These observations provide a rationale for the following studies of opiate antagonists. A double-blind study of bolus administration of naloxone followed by continuous infusion showed that this agent significantly decreased the amount of food consumed during a binge in 5 bulimia women [Mitchell et al, 1986] and an open-label trial of naltrexone also reported a significant reduction in bulimic symptomatology [Jonas and Gold, 1986]. These observations led to a placebo-controlled, double-blind cross-over study of naltrexone, a long-acting orally active narcotic antagonist, which failed to show a significant reduction in binge eating or vomiting episodes, although the dosage used in this study was relatively low in order to avoid the hepatotoxicity associated with high-dose therapy [Mitchell et al, 1989b].…”

Section: Opiate Antagonistsmentioning

confidence: 99%

Drug Treatment for Bulimia nervosa

Freeman

1998

Neuropsychobiology

View full text Add to dashboard Cite

Naloxone but not CCK-8 may attenuate binge-eating behavior in patients with the bulimia syndrome

Cited by 86 publications

References 29 publications

A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa

A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa

An Approach to the Development of Drugs for Appetite Disorders

Drug Treatment for Bulimia nervosa

Contact Info

Product

Resources

About